Market Cap | 199.56B | P/E | 6.97 | EPS this Y | 42.90% | Ern Qtrly Grth | -98.20% |
Income | -2.59B | Forward P/E | 11.51 | EPS next Y | 8.70% | 50D Avg Chg | -6.00% |
Sales | 55.17B | PEG | 0.59 | EPS past 5Y | -3.07% | 200D Avg Chg | -17.00% |
Dividend | 5.00% | Price/Book | 1.98 | EPS next 5Y | 18.60% | 52W High Chg | -36.00% |
Recommedations | 2.40 | Quick Ratio | 0.51 | Shares Outstanding | 5.67B | 52W Low Chg | - |
Insider Own | 0.05% | ROA | 0.94% | Shares Float | 5.66B | Beta | 0.62 |
Inst Own | 67.52% | ROE | -2.74% | Shares Shorted/Prior | 74.84M/61.73M | Price | 35.35 |
Gross Margin | 60.16% | Profit Margin | -4.70% | Avg. Volume | 26,886,577 | Target Price | 33.34 |
Oper. Margin | 22.40% | Earnings Date | Oct 29 | Volume | 34,241,200 | Change | -0.73% |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Gottlieb Scott | Director Director | Dec 15 | Buy | 26.4670 | 3,000 | 79,401 | 9,000 | 12/19/23 |
McDermott Michael | Executive Vice Presi.. Executive Vice President | Feb 25 | Option | 22.89 | 14,178 | 324,534 | 93,099 | 02/28/23 |
DAMICO JENNIFER B. | SVP & Controller SVP & Controller | Feb 25 | Option | 22.89 | 11,150 | 255,224 | 27,893 | 02/28/23 |
SUSMAN SALLY | Executive Vice Presi.. Executive Vice President | Feb 25 | Option | 22.89 | 72,984 | 1,670,604 | 209,179 | 02/28/23 |
Hwang Angela | President, Global Bi.. President, Global Biopharma | Feb 25 | Option | 22.89 | 20,273 | 464,049 | 44,541 | 02/28/23 |
JOHNSON RADY A | Executive Vice Presi.. Executive Vice President | Feb 25 | Option | 22.89 | 33,654 | 770,340 | 116,473 | 02/28/23 |
Hwang Angela | President, Global Bi.. President, Global Biopharmaceu | Feb 22 | Option | 30.17 | 57,032 | 1,720,655 | 67,027 | 02/24/23 |
SUSMAN SALLY | Executive Vice Presi.. Executive Vice President | Feb 22 | Option | 30.17 | 76,043 | 2,294,217 | 195,493 | 02/24/23 |
SAHNI PAYAL | Executive Vice Presi.. Executive Vice President | Feb 22 | Option | 30.17 | 15,209 | 458,856 | 32,671 | 02/24/23 |
McDermott Michael | Executive Vice Presi.. Executive Vice President | Feb 22 | Option | 30.17 | 13,307 | 401,472 | 88,957 | 02/24/23 |
JOHNSON RADY A | Executive Vice Presi.. Executive Vice President | Feb 22 | Option | 30.17 | 31,558 | 952,105 | 106,556 | 02/24/23 |
DAMICO JENNIFER B. | SVP & Controller SVP & Controller | Feb 22 | Option | 30.17 | 10,456 | 315,458 | 21,584 | 02/24/23 |
LANKLER DOUGLAS M | Executive Vice Presi.. Executive Vice President | Dec 14 | Option | 26.53 | 101,658 | 2,696,987 | 180,461 | 12/16/22 |
BOURLA ALBERT | Chairman & CEO Chairman & CEO | Dec 15 | Option | 26.53 | 222,328 | 5,898,362 | 411,890 | 12/16/22 |
DAMICO JENNIFER B. | SVP & Controller SVP & Controller | May 13 | Sell | 50.5000 | 4,000 | 202,000 | 15,064 | 05/17/22 |
SAHNI PAYAL | Executive Vice Presi.. Executive Vice President | May 13 | Sell | 49.8400 | 1,408 | 70,175 | 17,372 | 05/16/22 |
Carapezzi William R JR | Executive Vice Presi.. Executive Vice President | May 12 | Sell | 50.0000 | 32,908 | 1,645,400 | 38,146 | 05/13/22 |
LANKLER DOUGLAS M | Executive Vice Presi.. Executive Vice President | May 12 | Sell | 49.4100 | 38,273 | 1,891,069 | 78,803 | 05/13/22 |
Dolsten Mikael | President R&D President R&D | May 11 | Sell | 49.34 | 63,902 | 3,152,925 | 333,342 | 05/12/22 |
SUSMAN SALLY | Executive Vice Presi.. Executive Vice President | Feb 26 | Option | 25.6 | 63,580 | 1,627,648 | 172,880 | 03/01/22 |
DAMELIO FRANK A | Executive Vice Presi.. Executive Vice President | Feb 26 | Option | 25.6 | 127,160 | 3,255,296 | 649,918 | 03/01/22 |
SUSMAN SALLY | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 76,895 | 2,102,309 | 166,470 | 02/25/22 |
SAHNI PAYAL | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 13,884 | 379,589 | 29,391 | 02/25/22 |
LANKLER DOUGLAS M | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 115,342 | 3,153,450 | 181,659 | 02/25/22 |
JOHNSON RADY A | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 35,457 | 969,394 | 91,301 | 02/25/22 |
Hwang Angela | Group President Group President | Feb 23 | Option | 27.34 | 21,359 | 583,955 | 21,359 | 02/25/22 |
DAMELIO FRANK A | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 153,789 | 4,204,591 | 636,977 | 02/25/22 |
DAMICO JENNIFER B. | SVP & Controller SVP & Controller | Feb 23 | Option | 27.34 | 11,748 | 321,190 | 21,668 | 02/25/22 |
Carapezzi William R JR | Executive Vice Presi.. Executive Vice President | Feb 23 | Option | 27.34 | 25,632 | 700,779 | 82,914 | 02/25/22 |
YOUNG JOHN D | Group President Group President | Nov 11 | Sell | 50.09 | 150,000 | 7,513,500 | 312,704 | 11/12/21 |